Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1948 9
1950 1
1951 3
1953 2
1954 3
1955 2
1956 4
1957 3
1958 5
1959 1
1960 1
1961 9
1962 7
1963 2
1964 3
1965 2
1966 5
1967 7
1968 8
1969 4
1970 4
1971 3
1972 1
1973 5
1974 5
1975 5
1976 1
1977 3
1978 5
1979 5
1980 4
1981 4
1982 6
1983 1
1984 15
1985 16
1986 6
1987 10
1988 8
1989 6
1990 10
1991 10
1992 5
1993 5
1994 11
1995 4
1996 8
1997 9
1998 8
1999 8
2000 8
2001 11
2002 21
2003 24
2004 18
2005 20
2006 24
2007 23
2008 24
2009 24
2010 36
2011 46
2012 81
2013 56
2014 82
2015 65
2016 64
2017 67
2018 76
2019 109
2020 140
2021 130
2022 152
2023 158
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

1,569 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Among authors: vogel a. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Hepatocellular carcinoma.
Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Vogel A, et al. Lancet. 2022 Oct 15;400(10360):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6. Lancet. 2022. PMID: 36084663 Review.
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. Reig M, et al. Among authors: vogel a. J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19. J Hepatol. 2022. PMID: 34801630 Free PMC article. Review.
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Lordick F, et al. Among authors: vogel a. Ann Oncol. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. Epub 2022 Jul 29. Ann Oncol. 2022. PMID: 35914639 Free article. No abstract available.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B,… See abstract for full author list ➔ Pfister D, et al. Among authors: vogel a. Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24. Nature. 2021. PMID: 33762733 Free PMC article.
Metabolic support by macrophages sustains colonic epithelial homeostasis.
Fritsch SD, Sukhbaatar N, Gonzales K, Sahu A, Tran L, Vogel A, Mazic M, Wilson JL, Forisch S, Mayr H, Oberle R, Weiszmann J, Brenner M, Vanhoutte R, Hofmann M, Pirnes-Karhu S, Magnes C, Kühnast T, Weckwerth W, Bock C, Klavins K, Hengstschläger M, Moissl-Eichinger C, Schabbauer G, Egger G, Pirinen E, Verhelst SHL, Weichhart T. Fritsch SD, et al. Among authors: vogel a. Cell Metab. 2023 Nov 7;35(11):1931-1943.e8. doi: 10.1016/j.cmet.2023.09.010. Epub 2023 Oct 6. Cell Metab. 2023. PMID: 37804836 Free article.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: vogel a. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Systemic therapy of advanced hepatocellular carcinoma.
Galle PR, Dufour JF, Peck-Radosavljevic M, Trojan J, Vogel A. Galle PR, et al. Among authors: vogel a. Future Oncol. 2021 Apr;17(10):1237-1251. doi: 10.2217/fon-2020-0758. Epub 2020 Dec 14. Future Oncol. 2021. PMID: 33307782 Free article. Review.
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, Primrose JN, Rimassa L, Stenzinger A, Valle JW, Ducreux M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Vogel A, et al. Ann Oncol. 2023 Feb;34(2):127-140. doi: 10.1016/j.annonc.2022.10.506. Epub 2022 Nov 10. Ann Oncol. 2023. PMID: 36372281 Free article. No abstract available.
FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A, Segatto O, Stenzinger A, Saborowski A. Vogel A, et al. Annu Rev Med. 2023 Jan 27;74:293-306. doi: 10.1146/annurev-med-042921-024707. Epub 2022 Sep 28. Annu Rev Med. 2023. PMID: 36170665 Free article. Review.
1,569 results